The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder

Bibliography

• RAYCHAUDHURI SP, FARBER EM: The prevalence of psoriasis in the world. J. Eur. Acad. Dermatol. Venereol. (2001) 15(1):16-17.
   PubMed Web of Science ®Google Scholar
• SCHAFER T: Epidemiology of psoriasis. Review and the German perspective. Dermatology (2006) 212(4):327-337.
   PubMed Web of Science ®Google Scholar
• CHRISTOPHERS E, HENSELER T: Patient subgroups and the inflammatory pattern in psoriasis. Acta Derm. Venereol. Suppl. (Stockh) (1989) 151:88-92; discussion 106-110.
   PubMedGoogle Scholar
• BOWCOCK AM, KRUEGER JG: Getting under the skin: the immunogenetics of psoriasis. Nat. Rev. Immunol. (2005) 5(9):699-711.
   PubMed Web of Science ®Google Scholar
• ELDER JT: PSORS1: linking genetics and immunology. J. Invest. Dermatol. (2006) 126(6):1205-1206.
   PubMed Web of Science ®Google Scholar
• NAIR RP, STUART PE, NISTOR I et al.: Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am. J. Hum. Genet. (2006) 78(5):827-851.
   PubMed Web of Science ®Google Scholar
• CHRISTOPHERS E: Psoriasis-epidemiology and clinical spectrum. Clin. Exp. Dermatol. (2001) 26(4):314-320.
   PubMed Web of Science ®Google Scholar
• SCHON MP, BOEHNCKE WH: Psoriasis. N. Engl. J. Med. (2005) 352(18):1899-1912.
   PubMed Web of Science ®Google Scholar
• GELFAND JM, GLADMAN DD, MEASE PJ et al.: Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol. (2005) 53(4):573.
   PubMed Web of Science ®Google Scholar
• GISONDI P, GIROLOMONI G, SAMPOGNA F, TABOLLI S, ABENI D: Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur. J. Dermatol. (2005) 15(4):279-283.
   PubMed Web of Science ®Google Scholar
• ROWLANDS CG, DANBY FW: Histopathology of psoriasis treated with zinc pyrithione. Am. J. Dermatopathol. (2000) 22(3):272-276.
   PubMedGoogle Scholar
• HEYDENDAEL VM, SPULS PI, OPMEER BC et al.: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. (2003) 349(7):658-665.
   PubMed Web of Science ®Google Scholar
• TETT SE, TRIGGS EJ: Use of methotrexate in older patients. A risk-benefit assessment. Drugs Aging (1996) 9(6):458-471.
   PubMedGoogle Scholar
• IMOKAWA S, COLBY TV, LESLIE KO, HELMERS RA: Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur. Respir. J. (2000) 15(2):373-381.
   PubMed Web of Science ®Google Scholar
• HALLORAN PF, KUNG L, NOUJAIM J: Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant. Proc. (1998) 30(5):2167-2170.
   PubMed Web of Science ®Google Scholar
• LUDWIG-PEITSCH, KEMMLER N, GOERDT S, GOEBELER M: Klassische systemische therapie der psoriasis. Aktuelle Dermatologie (2006) 32:190-200.
   Google Scholar
• COCKERILL GW, BERT AG, RYAN GR et al.: Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood (1995) 86(7):2689-2698.
   PubMedGoogle Scholar
• TEUNISSEN MB, DE JAGER MH, KAPSENBERG ML, BOS JD: Inhibitory effect of cyclosporin A on antigen and alloantigen presenting capacity of human epidermal Langerhans cells. Br. J. Dermatol. (1991) 125(4):309-316.
   PubMedGoogle Scholar
• AL-DARAJI WI, GRANT KR, RYAN K, SAXTON A, REYNOLDS NJ: Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J. Invest. Dermatol. (2002) 118(5):779-788.
   PubMed Web of Science ®Google Scholar
• OJEDA R, SANCHEZ REGANA M, MASSANA J, OLIETE R, UMBERT P: Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study. J. Dermatol. Treat. (2005) 16(4):238-241.
   PubMed Web of Science ®Google Scholar
• SAURAT JH: Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J. Am. Acad. Dermatol. (1999) 41(3 Pt 2):S2-S6.
   PubMed Web of Science ®Google Scholar
• TANEW A, GUGGENBICHLER A, HONIGSMANN H, GEIGER JM, FRITSCH P: Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J. Am. Acad. Dermatol. (1991) 25(4):682-684.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS CE, CLARK CM, CHALMERS RJ, LI WAN PO A, WILLIAMS HC: A systematic review of treatments for severe psoriasis. Health Technol. Assess. (2000) 4(40):1-125.
   PubMedGoogle Scholar
• LITJENS NH, RADEMAKER M, RAVENSBERGEN B et al.: Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur. J. Immunol. (2004) 34(2):565-575.
   PubMed Web of Science ®Google Scholar
• LOEWE R, HOLNTHONER W, GROGER M et al.: Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J. Immunol. (2002) 168(9):4781-4787.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, ASADULLAH K: Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med. (2005) 11(1):43-48.
   PubMed Web of Science ®Google Scholar
• GOLLNICK H, ALTMEYER P, KAUFMANN R et al.: Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology (2002) 205(1):46-53.
   PubMed Web of Science ®Google Scholar
• ALTMEYER P, HARTWIG R, MATTHES U: [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients]. Hautarzt (1996) 47(3):190-196.
   PubMed Web of Science ®Google Scholar
• LANGNER A RJ, BARAN E, PLACEK W: Fumaric acid ester for the treatment of severe forms of psoriasis. Result of a Phase II clinical study. Eur. Acad. Dermatol. Venereol. (2004):S296/THER 235.
   Google Scholar
• BARKER JN: Psoriasis as a T cell-mediated autoimmune disease. Hosp. Med. (1998) 59(7):530-533.
   PubMed Web of Science ®Google Scholar
• OZAWA M, AIBA S: Immunopathogenesis of psoriasis. Curr. Drug Targets Inflamm. Allergy (2004) 3(2):137-144.
   PubMedGoogle Scholar
• DA SILVA AJ, BRICKELMAIER M, MAJEAU GR et al.: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J. Immunol. (2002) 168(9):4462-4471.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, CHRISTOPHERS E, LANGLEY R et al.: An international, randomized, double-blind, placebo-controlled Phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. (2003) 139(6):719-727.
   PubMed Web of Science ®Google Scholar
• KRUEGER GG, ELLIS CN: Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br. J. Dermatol. (2003) 148(4):784-788.
   PubMed Web of Science ®Google Scholar
• PARISER DM, GORDON KB, PAPP KA et al.: Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J. Cutan. Med. Surg. (2005) 9(6):303-312.
   Google Scholar
• SCHEINFELD N: Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin. Drug Saf. (2006) 5(2):197-209.
   PubMed Web of Science ®Google Scholar
• LEONARDI CL: Efalizumab in the treatment of psoriasis. Dermatol. Ther. (2004) 17(5):393-400.
   PubMedGoogle Scholar
• PAPP KA, HO V, LANGLEY R et al.: Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. J. Cutan. Med. Surg. (2006) 9(Suppl. 1):26-32.
   PubMedGoogle Scholar
• SKOV L, KRAGBALLE K, ZACHARIAE C et al.: HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol. (2003) 139(11):1433-1439.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, LEBWOHL M, SHIRIN S et al.: Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J. Am. Acad. Dermatol. (2000) 43(4):595-604.
   PubMed Web of Science ®Google Scholar
• LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. (2003) 349(21):2014-2022.
   PubMed Web of Science ®Google Scholar
• PAPP KA, TYRING S, LAHFA M et al.: A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. (2005) 152(6):1304-1312.
   PubMed Web of Science ®Google Scholar
• GORDON KB, GOTTLIEB AB, LEONARDI CL et al.: Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J. Dermatol. Treat. (2006) 17(1):9-17.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, KIVITZ AJ, BURCH FX et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J. Rheumatol. (2006) 33(4):712-721.
   PubMed Web of Science ®Google Scholar
• KOO J, KHERA P: Update on the mechanisms and efficacy of biological therapies for psoriasis. J. Dermatol. Sci. (2005) 38(2):75-87.
   PubMed Web of Science ®Google Scholar
• PATEL T, GORDON KB: Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol. Ther. (2004) 17(5):427-431.
   PubMedGoogle Scholar
• MEASE PJ, GLADMAN DD, RITCHLIN CT et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2005) 52(10):3279-3289.
   PubMed Web of Science ®Google Scholar
• TEN HOVE T, VAN MONTFRANS C, PEPPELENBOSCH MP, VAN DEVENTER SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut (2002) 50(2):206-211.
   PubMed Web of Science ®Google Scholar
• KRUGER-KRASAGAKIS S, GALANOPOULOS VK, GIANNIKAKI L, STEFANIDOU M, TOSCA AD: Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br. J. Dermatol. (2006) 154(3):460-466.
   PubMed Web of Science ®Google Scholar
• CHAUDHARI U, ROMANO P, MULCAHY LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 357(9271):1842-1847.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, EVANS R, LI S et al.: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. (2004) 51(4):534-542.
   PubMed Web of Science ®Google Scholar
• REICH K, NESTLE FO, PAPP K et al.: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet (2005) 366(9494):1367-1374.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A, ANTONI CE, GLADMAN D et al.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann. Rheum. Dis. (2006) 65(8):1038-1043.
   PubMed Web of Science ®Google Scholar
• PAPP KA: The long-term efficacy and safety of new biological therapies for psoriasis. Arch. Dermatol. Res. (2006) 298(1):7-15.
   PubMed Web of Science ®Google Scholar
• VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology (2003) 124(7):1774-1785.
   PubMed Web of Science ®Google Scholar
• KORMAN NJ, MOUL DK: Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use. Semin. Cutan. Med. Surg. (2005) 24(1):10-18.
   PubMed Web of Science ®Google Scholar
• GORDON K, KORMAN N, FRANKEL E et al.: Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J. Am. Acad. Dermatol. (2006) 54(3 Suppl. 2):S101-S111.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, KARABIN GD, BARKER JN et al.: Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am. J. Pathol. (1991) 138(1):129-140.
   PubMed Web of Science ®Google Scholar
• STRATIS A, PASPARAKIS M, RUPEC RA et al.: Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J. Clin. Invest. (2006) 116(8):2094-2104.
   PubMed Web of Science ®Google Scholar
• WANG H, PETERS T, KESS D et al.: Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J. Clin. Invest. (2006) 116(8):2105-2114.
   PubMed Web of Science ®Google Scholar
• WOLLENBERG A, WAGNER M, GUNTHER S et al.: Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol. (2002) 119(5):1096-1102.
   PubMed Web of Science ®Google Scholar
• CURRY JL, QIN JZ, BONISH B et al.: Innate immune-related receptors in normal and psoriatic skin. Arch. Pathol. Lab. Med. (2003) 127(2):178-186.
   PubMed Web of Science ®Google Scholar
• LOWES MA, CHAMIAN F, ABELLO MV et al.: Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. USA (2005) 102(52):19057-19062.
   PubMed Web of Science ®Google Scholar
• RAGAZ A, ACKERMAN AB: Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am. J. Dermatopathol. (1979) 1(3):199-214.
   PubMedGoogle Scholar
• NESTLE FO, CONRAD C, TUN-KYI A et al.: Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. (2005) 202(1):135-143.
   PubMed Web of Science ®Google Scholar
• BOS JD, HAGENAARS C, DAS PK et al.: Predominance of ‘memory’ T cells (CD4+, CDw29+) over ‘naive’ T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch. Dermatol. Res. (1989) 281(1):24-30.
   PubMed Web of Science ®Google Scholar
• BOVENSCHEN HJ, SEYGER MM, VAN DE KERKHOF PC: Plaque psoriasis versus atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br. J. Dermatol. (2005) 153(1):72-78.
   PubMedGoogle Scholar
• SERVITJE O, BORDAS X, SERON D et al.: Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy. J. Cutan. Pathol. (1996) 23(5):431-436.
   PubMedGoogle Scholar
• SCHLAAK JF, BUSLAU M, JOCHUM W et al.: T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. (1994) 102(2):145-149.
   PubMed Web of Science ®Google Scholar
• AUSTIN LM, OZAWA M, KIKUCHI T, WALTERS IB, KRUEGER JG: The majority of epidermal T cells in Psoriasis vulgaris lesions can produce Type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a Type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. (1999) 113(5):752-759.
   PubMed Web of Science ®Google Scholar
• TEUNISSEN MB, KOOMEN CW, DE WAAL MALEFYT R, WIERENGA EA, BOS JD: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. (1998) 111(4):645-649.
   PubMed Web of Science ®Google Scholar
• CAMERON AL, KIRBY B, FEI W, GRIFFITHS CE: Natural killer and natural killer-T cells in psoriasis. Arch. Dermatol. Res. (2002) 294(8):363-369.
   PubMed Web of Science ®Google Scholar
• WILSON SB, DELOVITCH TL: Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. (2003) 3(3):211-222.
   PubMed Web of Science ®Google Scholar
• OTTAVIANI C, NASORRI F, BEDINI C et al.: CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur. J. Immunol. (2006) 36(1):118-128.
   PubMed Web of Science ®Google Scholar
• GIRARDI M: Cutaneous biology of gammadelta T cells. Adv. Dermatol. (2004) 20:203-215.
   PubMedGoogle Scholar
• GIRARDI M, LEWIS J, GLUSAC E et al.: Resident skin-specific gammadelta T cells provide local, nonredundant regulation of cutaneous inflammation. J. Exp. Med. (2002) 195(7):855-867.
   PubMedGoogle Scholar
• SUGIYAMA H, GYULAI R, TOICHI E et al.: Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. (2005) 174(1):164-173.
   PubMed Web of Science ®Google Scholar
• HANCOCK GE, KAPLAN G, COHN ZA: Keratinocyte growth regulation by the products of immune cells. J. Exp. Med. (1988) 168(4):1395-1402.
   PubMed Web of Science ®Google Scholar
• OLANIRAN AK, BAKER BS, GARIOCH JJ, POWLES AV, FRY L: A comparison of the stimulatory effects of cytokines on normal and psoriatic keratinocytes in vitro. Arch. Dermatol. Res. (1995) 287(3-4):231-236.
   PubMedGoogle Scholar
• ELDER JT, FISHER GJ, LINDQUIST PB et al.: Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (1989) 243(4892):811-814.
   PubMed Web of Science ®Google Scholar
• HIGASHIYAMA M, MATSUMOTO K, HASHIMOTO K, YOSHIKAWA K: Increased production of transforming growth factor-alpha in psoriatic epidermis. J. Dermatol. (1991) 18(2):117-119.
   PubMedGoogle Scholar
• SCHULTZ GS, WHITE M, MITCHELL R et al.: Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science (1987) 235(4786):350-352.
   PubMed Web of Science ®Google Scholar
• FANTINI F, MAGNONI C, BRACCI-LAUDIERO L, PINCELLI CT: Nerve growth factor is increased in psoriatic skin. J. Invest. Dermatol. (1995) 105(6):854-855.
   PubMed Web of Science ®Google Scholar
• RAYCHAUDHURI SP, JIANG WY, SMOLLER BR, FARBER EM: Nerve growth factor and its receptor system in psoriasis. Br. J. Dermatol. (2000) 143(1):198-200.
   PubMed Web of Science ®Google Scholar
• RAYCHAUDHURI SP, SANYAL M, WELTMAN H, KUNDU-RAYCHAUDHURI S: K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J. Invest. Dermatol. (2004) 122(3):812-819.
   PubMed Web of Science ®Google Scholar
• BLUMBERG H, CONKLIN D, XU WF et al.: Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell (2001) 104(1):9-19.
   PubMed Web of Science ®Google Scholar
• KUNZ S, WOLK K, WITTE E et al.: Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp. Dermatol. (2006) 15(12):991-1004.
   PubMed Web of Science ®Google Scholar
• WOLK K, KUNZ S, ASADULLAH K, SABAT R: Cutting edge: immune cells as sources and targets of the IL-10 family members? J. Immunol. (2002) 168(11):5397-5402.
   Web of Science ®Google Scholar
• KINGO K, KOKS S, NIKOPENSIUS T, SILM H, VASAR E: Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. (2004) 5(2):117-121.
   PubMedGoogle Scholar
• KOKS S, KINGO K, RATSEP R et al.: Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun. (2004) 5(8):662-667.
   PubMed Web of Science ®Google Scholar
• KOKS S, KINGO K, VABR K et al.: Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun. (2005) 6(5):407-415.
   PubMed Web of Science ®Google Scholar
• OTKJAER K, KRAGBALLE K, FUNDING AT et al.: The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br. J. Dermatol. (2005) 153(5):911-918.
   PubMed Web of Science ®Google Scholar
• ROMER J, HASSELAGER E, NORBY PL et al.: Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J. Invest. Dermatol. (2003) 121(6):1306-1311.
   PubMed Web of Science ®Google Scholar
• WEI CC, CHEN WY, WANG YC et al.: Detection of IL-20 and its receptors on psoriatic skin. Clin. Immunol. (2005) 117(1):65-72.
   PubMedGoogle Scholar
• LIU L, DING C, ZENG W et al.: Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20. Blood (2003) 102(9):3206-3209.
   PubMed Web of Science ®Google Scholar
• CANDI E, SCHMIDT R, MELINO G: The cornified envelope: a model of cell death in the skin. Nat. Rev. Mol. Cell. Biol. (2005) 6(4):328-340.
   PubMed Web of Science ®Google Scholar
• WOLK K, WITTE E, WALLACE E et al.: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. (2006) 36(5):1309-1323.
   PubMed Web of Science ®Google Scholar
• WOLK K, SABAT R: Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. (2006) 17(5):367-380.
   PubMed Web of Science ®Google Scholar
• WOLK K, KUNZ S, WITTE E et al.: IL-22 increases the innate immunity of tissues. Immunity (2004) 21(2):241-254.
   PubMed Web of Science ®Google Scholar
• DONNELLY RP, SHEIKH F, KOTENKO SV, DICKENSHEETS H: The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol. (2004) 76(2):314-321.
   PubMedGoogle Scholar
• LANGER JA, CUTRONE EC, KOTENKO S: The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev. (2004) 15(1):33-48.
   PubMed Web of Science ®Google Scholar
• PESTKA S, KRAUSE CD, SARKAR D et al.: Interleukin-10 and related cytokines and receptors. Ann. Rev. Immunol. (2004) 22:929-979.
   PubMed Web of Science ®Google Scholar
• WOLK K, WITTE E, REINEKE U et al.: Is there an interaction between interleukin-10 and interleukin-22? Genes Immun. (2005) 6(1):8-18.
   PubMed Web of Science ®Google Scholar
• SANO S, CHAN KS, CARBAJAL S et al.: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. (2005) 11(1):43-49.
   PubMed Web of Science ®Google Scholar
• SANO S, ITAMI S, TAKEDA K et al.: Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. (1999) 18(17):4657-4668.
   PubMed Web of Science ®Google Scholar
• RUSZCZAK Z, DETMAR M, IMCKE E, ORFANOS CE: Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J. Invest. Dermatol. (1990) 95(6):693-699.
   PubMedGoogle Scholar
• MENTER A, GORDON K, CAREY W et al.: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch. Dermatol. (2005) 141(1):31-38.
   PubMed Web of Science ®Google Scholar
• BACHELEZ H, FLAGEUL B, DUBERTRET L et al.: Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. (1998) 11(1):53-62.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, MATHESON RT, LOWE N et al.: A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. (2003) 139(12):1627-1632; discussion 1632.
   PubMed Web of Science ®Google Scholar
• TYRING S, GOTTLIEB A, PAPP K et al.: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised Phase III trial. Lancet (2006) 367(9504):29-35.
   PubMed Web of Science ®Google Scholar
• MASTROIANNI A, MINUTILLI E, MUSSI A et al.: Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br. J. Dermatol. (2005) 153(3):531-536.
   PubMed Web of Science ®Google Scholar